Patents by Inventor Ka Hyon Park

Ka Hyon Park has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160193265
    Abstract: Disclosed is an antipyretic drug comprising a Stauntonia Hexaphylla leaf extract as an active ingredient. The antipyretic drug is developed based on the finding that the Stauntonia Hexaphylla leaf extract has no cytotoxicity and exhibits superior antipyretic effects, as compared to conventional antipyretic drugs having antipyretic effects. An antipyretic composition comprising the Stauntonia Hexaphylla leaf extract as an active ingredient exhibits potent antipyretic effect.
    Type: Application
    Filed: February 1, 2016
    Publication date: July 7, 2016
    Applicants: Jeonnam Bioindustry Foundation, YUNGJIN PHARM.CO., LTD.
    Inventors: Chul Yung CHOI, Sang O PAN, Hee Jin SEOL, Gyu Ok LEE, Ka Hyon PARK, Hee Sook KIM, Wook Jin JANG, Hyun KIM, Dong Wook LEE, Sun Oh KIM, Jae Gap KIM
  • Patent number: 9370542
    Abstract: Disclosed is an antipyretic drug comprising a Stauntonia Hexaphylla leaf extract as an active ingredient. The antipyretic drug is developed based on the finding that the Stauntonia Hexaphylla leaf extract has no cytotoxicity and exhibits superior antipyretic effects, as compared to conventional antipyretic drugs having antipyretic effects. An antipyretic composition comprising the Stauntonia Hexaphylla leaf extract as an active ingredient exhibits potent antipyretic effect.
    Type: Grant
    Filed: May 16, 2012
    Date of Patent: June 21, 2016
    Assignees: JEONNAM BIOINDUSTRY FOUNDATION, YUNGJIN PHARM.CO., LTD.
    Inventors: Chul Yung Choi, Sang O Pan, Hee Jin Seol, Gyu Ok Lee, Ka Hyon Park, Hee Sook Kim, Wook Jin Jang, Hyun Kim, Dong Wook Lee, Sun Oh Kim, Jae Gap Kim
  • Publication number: 20140205691
    Abstract: Disclosed is an antipyretic drug comprising a Stauntonia Hexaphylla leaf extract as an active ingredient. The antipyretic drug is developed based on the finding that the Stauntonia Hexaphylla leaf extract has no cytotoxicity and exhibits superior antipyretic effects, as compared to conventional antipyretic drugs having antipyretic effects. An antipyretic composition comprising the Stauntonia Hexaphylla leaf extract as an active ingredient exhibits potent antipyretic effect.
    Type: Application
    Filed: May 16, 2012
    Publication date: July 24, 2014
    Applicants: YUNGJIN PHARM.CO., LTD., JEONNAM BIOINDUSTRY FOUNDATION
    Inventors: Chul Yung Choi, Sang O Pan, Hee Jin Seol, Gyu Ok Lee, Ka Hyon Park, Hee Sook Kim, Wook Jin Jang, Hyun Kim, Dong Wook Lee, Sun Oh Kim, Jae Gap Kim